Biocogent teams with Felix Biotechnology on targeted antimicrobial tech
Felix Biotechnology specializes in targeted antimicrobial technologies, developing biotherapeutic solutions for the heath care industry and similar relevant applications. “Leveraging the potential of our technology across a range of applications allows us to have the biggest impact possible,” says Natalie Ma, Head of Business Development at Felix Biotechnology, is a recent media release about the partnership. “And,” she adds, “we are very excited to be working with a leader in the personal care and cosmetic space like Biocogent on this project.”
The San Francisco, California – based company was founded in 2019 and works closely with researchers at both Yale University and the University of California, Berkeley to address “urgent microbial challenges in human health and beyond.”
Biocogent partners with Felix Biotech on new skin care tech
Biocogent in a New York State – based personal care and cosmetic ingredient maker. The company, founded by Joseph Ceccoli, got its start in 2010 and today has a portfolio of ingredients spanning 4 product lines: DermalRx, a range that addresses skin renewal, anti-aging, and moisturization; Pleiotanicals, multifunctional plant-derived actives; HEDI, a line of ingredients made with high energy sonic technology; and a small line of what the company calls Advanced Solutions, ingredients that leverage leading-edge tech from in and beyond the company to meet nuanced market needs.
Now, in partnership with Felis Biotechnology, Biocogent the company has plans to develop skin care ingredients that eliminate or regulate what they’re calling “problematic bacteria” while leaving the “beneficial bacteria” undisturbed.
As Paul Lawrence, Director of Bioscience Research and Product Development at Biocogent, describes the partnership, “we are focused on providing our customers with access to a continuous resource of current scientific discoveries and cutting-edge research and development. The technology at Felix Biotechnology is novel and innovative, and we are excited to explore how these solutions can add value to our consumer products.”
The Felix Biotechnology approach to biotherapeutics seems well suited to the microbiome beauty ingredient market. And as Jonathan Kotula, Head of Science at Felix Biotechnology, explains in his recent remarks to the press, the company’s technologies are also resilient and in line with future-forward ingredient trends like sustainability/circularity.
“Our technology platform,” says Kotula, “allows us to quickly and efficiently develop custom solutions targeting specific microbes in complex environments.” And, he adds, “Our solutions are not only effective, but also nontoxic, environmentally friendly, and able to withstand the rigors of manufacturing and deployment across a range of environments.”
